Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut–liver axis

참고문헌 (125)

1. Cho, I, "The human microbiome: at the interface of health and disease", Nat. Rev. Genet, 13, pp.260~270 (2012)
2. Albillos, A., "The gut-liver axis in liver disease : Pathophysiological basis for therapy", J. Hepatol, 72, pp.558~577 (2020)
3. Fukui Hiroshi, "Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update", Gut and Liver, 15(5), pp.666~676 (2021), 거트앤리버 소화기연관학회협의회[DOI]
4. Tripathi, A., "The gut-liver axis and the intersection with the microbiome", Nat. Rev. Gastroenterol. Hepatol, 15, pp.397~411 (2018)
5. Hov, J. R., "The microbiota and the gut-liver axis in primary sclerosing cholangitis", Nat. Rev. Gastroenterol. Hepatol (2022)[DOI]
6. Ng, S. C., "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century : a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2017)
7. Kaplan, G. G., "The four epidemiological stages in the global evolution of inflammatory bowel disease", Nat. Rev. Gastroenterol. Hepatol, 18, pp.56~66 (2021)
8. 박상형, "Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?", Intestinal research, 20(2), pp.159~164 (2022), 대한장연구학회[DOI]
9. Molodecky, N. A., "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review", Gastroenterology, 142, pp.46~54 (2012)
10. Mahadevan, U., "Inflammatory bowel disease-gastroenterology diamond jubilee review", Gastroenterology, 154, pp.1555~1558 (2018)
11. Chang, J. T., "Pathophysiology of inflammatory bowel diseases", N. Engl. J. Med, 383, pp.2652~2664 (2020)
12. Ryu Okumura, "Roles of intestinal epithelial cells in the maintenance of gut homeostasis", Experimental and Molecular Medicine, 49, pp.1~8 (2017), 생화학분자생물학회
13. Harbord, M., "The first european evidence-based consensus on extraintestinal manifestations in inflammatory bowel disease", J. Crohns Colitis, 10, pp.239~254 (2016)
14. Vavricka, S. R., "Extraintestinal manifestations of inflammatory bowel disease", Inflamm. Bowel Dis, 21, pp.1982~1992 (2015)
15. Carolina Palmela, "Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features", Gut and Liver, 12(1), pp.17~29 (2018), 거트앤리버 소화기연관학회협의회
16. Rossi, R. E., "Primary sclerosing cholangitis associated with inflammatory bowel disease : an update", Eur. J. Gastroenterol. Hepatol, 28, pp.123~131 (2016)
17. Boonstra, K., "Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis", Hepatology, 58, pp.2045~2055 (2013)
18. Molodecky, N. A., "Incidence of primary sclerosing cholangitis : a systematic review and meta-analysis", Hepatology, 53, pp.1590~1599 (2011)
19. Chapman, R., "Diagnosis and management of primary sclerosing cholangitis", Hepatology, 51, pp.660~678 (2010)
20. Karlsen, T. H., "Primary sclerosing cholangitis-a comprehensive review", J. Hepatol, 67, pp.1298~1323 (2017)
21. Da Cunha, T., "Primary sclerosing cholangitis and inflammatory bowel disease : a review", J. Clin. Transl. Hepatol, 10, pp.531~542 (2022)
22. Bambha, K., "Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community", Gastroenterology, 125, pp.1364~1369 (2003)
23. Ang, T. L., "Clinical profile of primary sclerosing cholangitis in Singapore", J. Gastroenterol. Hepatol, 17, pp.908~913 (2002)
24. Takikawa, H., "Analysis of 388cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients", Hepatol. Res, 29, pp.153~159 (2004)
25. Ye, B. D., "Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea", Inflamm. Bowel Dis, 17, pp.1901~1906 (2011)
26. Arshdeep Singh, "Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India", Intestinal research, 21(4), pp.452~459 (2023), 대한장연구학회[DOI]
27. 박용은, "Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?", Intestinal research, 20(2), pp.157~158 (2022), 대한장연구학회[DOI]
28. Okolicsanyi, L., "Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group", Eur. J. Gastroenterol. Hepatol, 8, pp.685~691 (1996)
29. Meng-Tzu Weng, "Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease", Intestinal research, 20(2), pp.224~230 (2022), 대한장연구학회[DOI]
30. 송은미, "Natural history of inflammatory bowel disease: a comparison between the East and the West", Intestinal research, 20(4), pp.418~430 (2022), 대한장연구학회[DOI]
31. de Lange, K. M., "Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease", Nat. Genet, 49, pp.256~261 (2017)
32. Jostins, L., "Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease", Nature, 491, pp.119~124 (2012)
33. Bergquist, A., "Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis", Clin. Gastroenterol. Hepatol, 6, pp.939~943 (2008)
34. Karlsen, T. H., "Genome-wide association analysis in primary sclerosing cholangitis", Gastroenterology, 138, pp.1102~1111 (2010)
35. Jiang, X., "Genetics of primary sclerosing cholangitis and pathophysiological implications", Nat. Rev. Gastroenterol. Hepatol, 14, pp.279~295 (2017)
36. Germain, R. N., "MHC-dependent antigen processing and peptide presentation:providing ligands for T lymphocyte activation", Cell, 76, pp.287~299 (1994)
37. Wiencke, K., "Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles", Hepatology, 34, pp.625~630 (2001)
38. Schrumpf, E., "HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease", Scand. J. Gastroenterol, 17, pp.187~191 (1982)
39. Ponsioen, C. Y., "Immunohistochemical analysis of inflammation in primary sclerosing cholangitis", Eur. J. Gastroenterol. Hepatol, 11, pp.769~774 (1999)
40. Liu, J. Z., "Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis", Nat. Genet, 45, pp.670~675 (2013)
41. Ellinghaus, D., "Analysis of five chronic inflammatory diseases identifies 27new associations and highlights disease-specific patterns at shared loci", Nat. Genet, 48, pp.510~518 (2016)
42. Srivastava, B., "Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis", Scand. J. Gastroenterol, 47, pp.820~826 (2012)
43. Hov, J. R., "Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis", PLoS ONE, 5, pp.e12403~ (2010)
44. Mitro, N., "Insights in the regulation of cholesterol 7alpha-hydroxylase gene reveal a target for modulating bile acid synthesis", Hepatology, 46, pp.885~897 (2007)
45. Ellinghaus, D., "Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4", Hepatology, 58, pp.1074~1083 (2013)
46. Ji, S. G., "Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease", Nat. Genet, 49, pp.269~273 (2017)
47. Mueller, T., "Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis", Liver Int, 31, pp.1574~1588 (2011)
48. Fiorotto, R., "Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-kappaB-mediated inflammatory response in mice", Gastroenterology, 141, pp.1498~1508 (2011)[DOI]
49. Bird, T. G., "Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling", Proc. Natl. Acad. Sci. USA, 110, pp.6542~6547 (2013)
50. Harada, K., "Biliary innate immunity: function and modulation", Mediators Inflamm (2010)[DOI]
51. Harada, K., "Innate immunity in the pathogenesis of cholangiopathy : a recent update", Inflamm. Allergy Drug Targets, 11, pp.478~483 (2012)
52. Strazzabosco, M., "Pathophysiology of cholangiopathies", J. Clin. Gastroenterol, 39, pp.S90~S102 (2005)
53. Gilmore, T. D., "Introduction to NF-kappaB: players, pathways, perspectives", Oncogene, 25, pp.6680~6684 (2006)
54. Sollid, L. M., "Triggers and drivers of autoimmunity : lessons from coeliac disease", Nat. Rev. Immunol, 13, pp.294~302 (2013)
55. Chen, K., "Th17 cells mediate clade-specific, serotype-independent mucosal immunity", Immunity, 35, pp.997~1009 (2011)
56. Miossec, P., "Interleukin-17 and type 17 helper T cells", N. Engl. J. Med, 361, pp.888~898 (2009)
57. Katt, J., "Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis", Hepatology, 58, pp.1084~1093 (2013)
58. Hsu, W., "Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(-", -)mice, 2009, pp.49, 133~140
59. Hov, J. R., "Autoantibodies in primary sclerosing cholangitis", World J. Gastroenterol, 14, pp.3781~3791 (2008)
60. Hov, J. R., "Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis", Liver Int, 37, pp.458~465 (2017)
61. Stinton, L. M., "PR3-ANCA : a promising biomarker in primary sclerosing cholangitis(PSC)", PLoS ONE, 9, pp.e112877~ (2014)
62. Culver, E. L., "Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis", Liver Int, 40, pp.2744~2757 (2020)
63. 이성희, "Intestinal Permeability Regulation by Tight Junction: Implication on Inflammatory Bowel Diseases", Intestinal research, 13(1), pp.11~18 (2015), 대한장연구학회[DOI]
64. Tabibian, J. H., "The enteric microbiome in hepatobiliary health and disease", Liver Int, 36, pp.480~487 (2016)
65. Cesaro, C., "Gut microbiota and probiotics in chronic liver diseases", Dig. Liver Dis, 43, pp.431~438 (2011)
66. Ong, J., "Does colectomy affect the progression of primary sclerosing cholangitis? A systematic review and metaanalysis", Gastroenterol. Hepatol. Bed Bench, 11, pp.277~283 (2018)
67. Grant, A. J., "Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease", Lancet, 359, pp.150~157 (2002)
68. Trivedi, P. J., "Mucosal immunity in liver autoimmunity : a comprehensive review", J. Autoimmun, 46, pp.97~111 (2013)
69. Trauner, M., "Molecular pathogenesis of cholestasis", N. Engl. J. Med, 339, pp.1217~1227 (1998)
70. Hohenester, S., "A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes", Hepatology, 55, pp.173~183 (2012)
71. Jia, W., "Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis", Nat. Rev. Gastroenterol. Hepatol, 15, pp.111~128 (2018)
72. Poupon, R., "Chronic cholestatic diseases", J. Hepatol, 32, pp.129~140 (2000)
73. Bell, L. N., "Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis", Liver Int, 35, pp.263~274 (2015)
74. Kawamata, Y., "A G protein-coupled receptor responsive to bile acids", J. Biol. Chem, 278, pp.9435~9440 (2003)
75. Vavassori, P., "The bile acid receptor FXR is a modulator of intestinal innate immunity", J. Immunol, 183, pp.6251~6261 (2009)
76. Reich, M., "Downregulation of TGR5(GPBAR1)in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis", J. Hepatol, 75, pp.634~646 (2021)
77. Milkiewicz, M., "Impaired hepatic adaptation to chronic cholestasis induced by primary sclerosing cholangitis", Sci. Rep, 6, pp.39573~ (2016)
78. Kempinska-Podhorodecka, A., "Role of miR-506 in ulcerative colitis associated with primary sclerosing cholangitis", Sci. Rep, 11, pp.10134~ (2021)
79. Hang, S., "Bile acid metabolites control T(H)17 and T(reg)cell differentiation", Nature, 576, pp.143~148 (2019)
80. de Aguiar Vallim, T. Q, "Pleiotropic roles of bile acids in metabolism", Cell Metab, 17, pp.657~669 (2013)
81. Sagar, N. M., "The interplay of the gut microbiome, bile acids, and volatile organic compounds", Gastroenterol. Res. Pract, 2015, pp.398585~ (2015)
82. Quraishi, M. N., "A pilot integrative analysis of colonic gene expression, gut microbiota, and immune infiltration in primary sclerosing cholangitisinflammatory bowel disease : association of disease with bile acid pathways", J. Crohns Colitis, 14, pp.935~947 (2020)
83. Tabibian, J. H., "Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis", Hepatology, 59, pp.2263~2275 (2014)
84. Bogert, P. S., "Cellular senescence in the cholangiopathies", Curr. Opin. Gastroenterol, 38, pp.121~127 (2022)
85. Alvaro, D., "Regulation and deregulation of cholangiocyte proliferation", J. Hepatol, 33, pp.333~340 (2000)
86. Zimmermann, H. W., "Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis", Inflamm. Allergy Drug Targets, 10, pp.509~536 (2011)
87. Mederacke, I., "Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology", Nat. Commun, 4, pp.2823~ (2013)
88. Alipour, M., "Mucosal barrier depletion and loss of bacterial diversity are primary abnormalities in paediatric ulcerative colitis", J. Crohns Colitis, 10, pp.462~471 (2016)
89. Pittayanon, R., "Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review", Gastroenterology, 158, pp.930~946 (2020)
90. Kummen, M., "Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis", Gastroenterology, 160, pp.1784~1798 (2021)
91. Sabino, J., "Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD", Gut, 65, pp.1681~1689 (2016)
92. Kummen, M., "The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls", Gut, 66, pp.611~619 (2017)
93. Hov, J. R., "The microbiome in primary sclerosing cholangitis : current evidence and potential concepts", Semin. Liver Dis, 37, pp.314~331 (2017)
94. Bajer, L., "Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis", World J. Gastroenterol, 23, pp.4548~4558 (2017)
95. Schrumpf, E., "The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation", J. Hepatol, 66, pp.382~389 (2017)
96. Tabibian, J. H., "Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis", Hepatology, 63, pp.185~196 (2016)
97. Nakamoto, N., "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis", Nat. Microbiol, 4, pp.492~503 (2019)
98. Tabibian, J. H., "Role of the microbiota and antibiotics in primary sclerosing cholangitis", Biomed. Res. Int, 2013, pp.389537~ (2013)
99. Tedesco, D., "Alterations in intestinal microbiota lead to production of interleukin 17 by intrahepatic gammadelta T-cell receptor-positive cells and pathogenesis of cholestatic liver disease", Gastroenterology, 154, pp.2178~2193 (2018)
100. Mouchli, M. A., "Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis", Inflamm. Bowel Dis, 24, pp.1074~1081 (2018)
101. Lunder, A. K., "Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease", Gastroenterology, 151, pp.660~669 (2016)
102. Schaeffer, D. F., "The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis", Dig. Dis. Sci, 58, pp.2608~2614 (2013)
103. Boonstra, K., "Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease", Inflamm. Bowel Dis, 18, pp.2270~2276 (2012)
104. O’Toole, A., "Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease", Clin. Gastroenterol. Hepatol, 10, pp.439~441 (2012)
105. de Vries, A. B., "Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis", World J. Gastroenterol, 21, pp.1956~1971 (2015)
106. Marelli, L., "Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?", Gut, 60, pp.1224~1228 (2011)
107. Verdonk, R. C., "Inflammatory bowel disease after liver transplantation : risk factors for recurrence and de novo disease", Am. J. Transpl, 6, pp.1422~1429 (2006)
108. Fraga, M., "Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study : prevalence, risk factors, and long-term follow-up", Eur. J. Gastroenterol. Hepatol, 29, pp.91~97 (2017)
109. Kim, W. R., "A revised natural history model for primary sclerosing cholangitis", Mayo Clin. Proc, 75, pp.688~694 (2000)
110. Weismuller, T. J., "Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis", Gastroenterology, 152, pp.1975~1984 (2017)
111. Ekbom, A., "Ulcerative colitis and colorectal cancer. A population-based study", N. Engl. J. Med, 323, pp.1228~1233 (1990)
112. Soetikno, R. M., "Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis : a meta-analysis", Gastrointest. Endosc, 56, pp.48~54 (2002)
113. Trivedi, P. J., "Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age", Gastroenterology, 159, pp.915~928 (2020)
114. Guerra, I., "Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients : a multicentre retrospective cohort study", J. Crohns Colitis, 13, pp.1492~1500 (2019)
115. Jorgensen, K. K., "Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation : a Nordic multicenter study", Scand. J. Gastroenterol, 47, pp.1021~1029 (2012)
116. Chapman, M. H., "British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis", Gut, 68, pp.1356~1378 (2019)
117. Singh, S., "Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease : a systematic review and meta-analysis", Inflamm. Bowel Dis, 19, pp.1631~1638 (2013)
118. Banales, J. M., "Expert consensus document : cholangiocarcinoma : current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS-CCA)", Nat. Rev. Gastroenterol. Hepatol, 13, pp.261~280 (2016)
119. Palmer, W. C., "Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma", J. Hepatol, 57, pp.69~76 (2012)
120. Ali, A. H., "Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis", Hepatology, 67, pp.2338~2351 (2018)
121. Gulamhusein, A. F., "Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD", Am. J. Gastroenterol, 111, pp.705~711 (2016)
122. Bowlus, C. L., "AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma", Hepatology, 77, pp.659~702 (2023)
123. Goeppert, B., "Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities", Hepatology, 72, pp.1253~1266 (2020)
124. Ong, C. K., "Exome sequencing of liver fluke-associated cholangiocarcinoma", Nat. Genet, 44, pp.690~693 (2012)
125. Zhang, Q., "Gut microbiome directs hepatocytes to Recruit MDSCs and promote cholangiocarcinoma", Cancer Discov, 11, pp.1248~1267 (2021)

관련 논문AI추천